The dynamics of molecular markers expression of blood lymphocytes activating at patients with an uveal melanoma at the different types of treatment

Purpose To study the dynamics of molecular markers expression of blood lymphocytes activating at patients with the uveal melanoma at the different types of treatment. Methods Research was conducted in the dynamics at patients (n=67) in age 63,4±5,7 years old with the uveal melanoma at the different types of treatment. The photocoagulation was conducted in the first group (n=42), the enucleation was in the second group (n=19), the combine therapy (photocoagulation + brachytherapy) was in the third group (n=6). The level of molecular markers expression of lymphocytes activating was determined by the gistoimmunocitochemical method through the monoclonal antibodies (CD7, CD25, CD38, CD45, CD54, CD150 and CD95). The estimation of statistical meaningfulness of distinctions was executed by Mann‐Whitney and Wilcoxon tests. Results Аfter the photocoagulation at patients with uveal melanoma was marked the reliable increase of molecular markers of lymphocytes activating (CD7, CD38, CD150 and CD95) as compared to indexes at the beginning of treatment. After the enucleation the level of molecular markers of lymphocytes activating (CD7 and CD95) was for certain increased as compared to the initial level. The combine therapy (photocoagulation + brachytherapy) was accompanied the reliable increase of activating markers (CD7, CD25, CD38, CD45, CD54, CD150 and CD95). Conclusion The highest level of the immune system activating is marked at the combine treatment. Less expressed activating at the enucleation and photocoagulation.